Cargando…

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagerman, Randi, Jacquemont, Sebastien, Berry-Kravis, Elizabeth, Des Portes, Vincent, Stanfield, Andrew, Koumaras, Barbara, Rosenkranz, Gerd, Murgia, Alessandra, Wolf, Christian, Apostol, George, von Raison, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242849/ https://www.ncbi.nlm.nih.gov/pubmed/30451888 http://dx.doi.org/10.1038/s41598-018-34978-4

Ejemplares similares

Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study
por: Bailey, Donald B., et al.
Publicado: (2015)

The challenges of clinical trials in fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2013)

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome
por: Hessl, David, et al.
Publicado: (2019)

Fragile X Premutation
por: Tassone, Flora, et al.
Publicado: (2014)

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
por: Berry-Kravis, E, et al.
Publicado: (2009)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis
por: Luu, Skylar, et al.
Publicado: (2020)

Arbaclofen in fragile X syndrome: results of phase 3 trials
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2017)

Best Practices in Fragile X Syndrome Treatment Development
por: Erickson, Craig A., et al.
Publicado: (2018)

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments
por: Hagerman, Randi, et al.
Publicado: (2010)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems
por: Hagerman, Randi J, et al.
Publicado: (2008)

Open-label add-on treatment trial of minocycline in fragile X syndrome
por: Paribello, Carlo, et al.
Publicado: (2010)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

Fragile X Premutation: Medications, Therapy and Lifestyle Advice
por: Sodhi, Deepika Kour, et al.
Publicado: (2021)

Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
por: Negida, Ahmed, et al.
Publicado: (2021)

Targeted treatments for fragile X syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2011)

Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome
por: Aishworiya, Ramkumar, et al.
Publicado: (2023)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2018)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2018)

Fragile X-Associated Neuropsychiatric Disorders (FXAND) in Young Fragile X Premutation Carriers
por: Aishworiya, Ramkumar, et al.
Publicado: (2022)

Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers
por: Polussa, Jonathan, et al.
Publicado: (2014)

Modulation of the GABAergic pathway for the treatment of fragile X syndrome
por: Lozano, Reymundo, et al.
Publicado: (2014)

Cardiovascular Problems in the Fragile X Premutation
por: Tassanakijpanich, Nattaporn, et al.
Publicado: (2020)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Fragile X-Associated Tremor/Ataxia Syndrome: Unmet Needs and a Path for the Future
por: Hall, Deborah A., et al.
Publicado: (2018)

Case Reports of Aortic Aneurism in Fragile X Syndrome
por: Lewis, Sivan, et al.
Publicado: (2022)

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2022)

Descriptive analysis of seizures and comorbidities associated with fragile X syndrome
por: Albizua, Igor, et al.
Publicado: (2022)

Fragile X Syndrome in children
por: Acero-Garcés, David O., et al.
Publicado: (2023)

Open-label pilot clinical trial of citicoline for fragile X-associated tremor/ataxia syndrome (FXTAS)
por: Hall, Deborah A., et al.
Publicado: (2020)

FMR1 premutation with Prader–Willi phenotype and fragile X‐associated tremor/ataxia syndrome
por: Martínez‐Cerdeño, Verónica, et al.
Publicado: (2017)

Treatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature
por: Tartaglia, Nicole, et al.
Publicado: (2019)

Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization
por: Cordeiro, Lisa, et al.
Publicado: (2010)

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
por: Berry-Kravis, Elizabeth, et al.
Publicado: (2012)

Neural progenitor cells from an adult patient with fragile X syndrome
por: Schwartz, Philip H, et al.
Publicado: (2005)

EEG Signal Complexity Is Reduced During Resting-State in Fragile X Syndrome
por: Proteau-Lemieux, Mélodie, et al.
Publicado: (2021)

Genomic studies in fragile X premutation carriers
por: Lozano, Reymundo, et al.
Publicado: (2014)

New Targeted Treatments for Fragile X Syndrome
por: Protic, Dragana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3ikk3pg552u075cdk006k56blc